Literature DB >> 31927102

Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients.

Swati Naik1, Spyridoula Vasileiou2, Paibel Aguayo-Hiraldo3, Shivani Mukhi2, Ghadir Sasa3, Caridad Martinez3, Robert A Krance3, Stephen Gottschalk3, Ann Leen3.   

Abstract

Serious viral infections, due to delayed immune reconstitution, are a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Thus, many transplant centers prospectively track cellular immune recovery by evaluating absolute cell numbers and the phenotypic profile of reconstituting T cell subsets to identify individuals who are at highest risk of infection. Conventional assessments, however, fail to measure either the antigen specificity or functional capacity of reconstituting cells-both factors that correlate with endogenous antiviral protection. In this pilot study, we sought to address this limitation by prospectively investigating the tempo of endogenous immune reconstitution in a cohort of 23 pediatric HSCT patients using both quantitative (flow cytometry) and qualitative (IFNγ ELISpot) measures, which we correlated with either the presence or absence of infections associated with cytomegalovirus, adenovirus, Epstein-Barr virus, BK virus, human herpes virus 6, respiratory syncytial virus, parainfluenza, influenza, and human metapneumovirus. We present data spanning 12 months post-transplant demonstrating the influence of conditioning on immune recovery and highlighting the differential impact of active viral replication on the quantity and quality of reconstituting cells. Judicious use of standard (phenotypic) and novel (functional) monitoring strategies can help guide the clinical care and personalized management of allogenic HSCT recipients with infections.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Functional immune reconstitution; Viral infections

Mesh:

Year:  2020        PMID: 31927102     DOI: 10.1016/j.bbmt.2020.01.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  24 in total

1.  Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.

Authors:  A Gratwohl; R Brand; F Frassoni; V Rocha; D Niederwieser; P Reusser; H Einsele; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

2.  Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.

Authors:  Sophie Servais; Etienne Lengline; Raphaël Porcher; Maryvonnick Carmagnat; Régis Peffault de Latour; Marie Robin; Flore Sicre de Fontebrune; Emmanuel Clave; Guitta Maki; Clémence Granier; Alienor Xhaard; Nathalie Dhedin; Jean-Michel Molina; Antoine Toubert; Hélène Moins-Teisserenc; Gérard Socie
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-07       Impact factor: 5.742

3.  Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT.

Authors:  L Król; J Stuchlý; P Hubáček; P Keslová; P Sedláček; J Starý; O Hrušák; T Kalina
Journal:  Bone Marrow Transplant       Date:  2010-11-08       Impact factor: 5.483

Review 4.  Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

5.  Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+ CD3+ count reconstitution is associated with survival.

Authors:  U Koehl; K Bochennek; S Y Zimmermann; T Lehrnbecher; J Sörensen; R Esser; C Andreas; C Kramm; H P Grüttner; E Falkenberg; A Orth; P Bader; D Schwabe; T Klingebiel
Journal:  Bone Marrow Transplant       Date:  2007-03       Impact factor: 5.483

Review 6.  T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Catherine M Bollard; Helen E Heslop
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

Review 7.  Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist.

Authors:  Natasha Kekre; Joseph H Antin
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

8.  Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Authors:  Ifigeneia Tzannou; Anastasia Papadopoulou; Swati Naik; Kathryn Leung; Caridad A Martinez; Carlos A Ramos; George Carrum; Ghadir Sasa; Premal Lulla; Ayumi Watanabe; Manik Kuvalekar; Adrian P Gee; Meng-Fen Wu; Hao Liu; Bambi J Grilley; Robert A Krance; Stephen Gottschalk; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen; Bilal Omer
Journal:  J Clin Oncol       Date:  2017-08-07       Impact factor: 44.544

9.  The impact of alternative donor types on viral infections in pediatric hematopoietic stem cell transplantation.

Authors:  D Atay; A Akcay; F Erbey; G Ozturk
Journal:  Pediatr Transplant       Date:  2018-01-03

10.  Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.

Authors:  Siok-Keen Tey; Glen A Kennedy; Deborah Cromer; Miles P Davenport; Susan Walker; Linda I Jones; Tania Crough; Simon T Durrant; James A Morton; Jason P Butler; Ashish K Misra; Geoffrey R Hill; Rajiv Khanna
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more
  2 in total

1.  Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Authors:  Hisham Abdel-Azim; Hema Dave; Kimberly Jordan; Stephanie Rawlings-Rhea; Annie Luong; Ashley L Wilson
Journal:  Cytotherapy       Date:  2021-10-26       Impact factor: 5.414

2.  Patient risk stratification and tailored clinical management of post-transplant CMV-, EBV-, and BKV-infections by monitoring virus-specific T-cell immunity.

Authors:  Anastasia Papadopoulou; Kiriakos Koukoulias; Maria Alvanou; Vassilios K Papadopoulos; Zoe Bousiou; Vasiliki Kalaitzidou; Fotini S Kika; Apostolia Papalexandri; Despina Mallouri; Ioannis Batsis; Ioanna Sakellari; Achilles Anagnostopoulos; Evangelia Yannaki
Journal:  EJHaem       Date:  2021-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.